Here is the design of a clinical trial:

Official Title: PHARM-MD; An Open-Label, Randomized Controlled Phase II Study to Evaluate the Efficacy of a Pharmacist Managed Diabetes Clinic in High-Risk Diabetes Patients

Included conditions:
- Diabetes Mellitus, Type 2

Study Armgroups:
- {'label': 'Standard of Care (SOC)', 'type': 'ACTIVE_COMPARATOR', 'description': "The control group patients will be managed by their assigned PCPs, per Standard of Care (SOC), per American Diabetes Association Guidelines. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP", 'interventionNames': ['Other: Standard of Care (SOC)']}
- {'label': 'SOC and PMDC', 'type': 'EXPERIMENTAL', 'description': 'The intervention group patients will be managed by their assigned primary care physicians (PCPs), per American Diabetes Association Guidelines for Standard of Care (SOC) and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The pharmacy managed diabetes clinic (PMDC) visit encounters will focus on patient identified goals for the management of their diabetes. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician.', 'interventionNames': ['Behavioral: Pharmacy Managed Diabetes Clinic (PMDC)', 'Other: Standard of Care (SOC)']}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'Pharmacy Managed Diabetes Clinic (PMDC)', 'description': 'The PMDC visit encounters will focus on patient identified goals for the management of their diabetes. Initial visit in the PMDC will be 60-90 minutes with follow up visits lasting 30-45 minutes.', 'armGroupLabels': ['SOC and PMDC']}
- {'type': 'OTHER', 'name': 'Standard of Care (SOC)', 'description': 'Standard of care will be delivered at the physician discretion per the current American Diabetes Association recommendations', 'armGroupLabels': ['SOC and PMDC', 'Standard of Care (SOC)']}

Primary Outcomes:
- {'measure': 'Hemoglobin A1c at 6 Months', 'description': 'change from baseline in Hemoglobin A1c, measured in % DCCT (Diabetes Control and Complications Trial) units', 'timeFrame': '6 months'}
- {'measure': 'Hemoglobin A1c at 12 Months', 'description': 'change from baseline in Hemoglobin A1c', 'timeFrame': '12 months'}

Please estimate the sample size based on the assumption: 
80% power, significance level of p < 0.05, and 20% attrition rate.
Sample size
        Assigning an allocation of 1:1 that will result in equal sample sizes, we are expecting a mean difference of change in HbA1c of 1% between the two groups (intervention versus control) with standard deviation (SD) of 1.5%. The sample size was estimated to be 36 per arm or a total of 72 with 80% power at a pâ<â0.05 significance. Adding 20% for attrition, the final sample size was estimated at 86 patients. We considered a HbA1c difference of 1% as being clinically significant in long-term reduction of stroke, myocardial infarction, and microvascular complications [3]. PASS 15 Power Analysis and Sample Size Software (2017). NCSS, LLC. Kaysville, UT, USA, ncss.com/software/pass was used for the sample size calculation.